Second-Line Axi-Cel Prolongs Survival Over SOC in Elderly Patients With R/R LBCL

The administration of axicabtagene ciloleucel in the second-line setting improved overall survival and progression-free survival vs standard-of-care treatment in patients with relapsed/refractory large B-cell lymphoma who are at least 65 years of age.

Related Keywords

Amsterdam ,Noord Holland ,Netherlands ,United States ,American ,Marie Jos ,American Society Of Hematology ,Amsterdam University Medical Centers ,Annual Meeting ,Amsterdam University Medical ,Cash ,Cart Cell Therapy ,Dlbcl ,Zuma 7 ,2023 Ash Annual Meeting ,Relapsed Refractory Largeb Cell Lymphoma ,Elderly ,